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Abstract: Objectives: For children with Juvenile Idiopathic Arthritis (JIA) who fail to respond to
methotrexate, the delay in identifying the optimal treatment at an early stage of disease
can lead to long-term joint damage. Recent studies indicate that relevant variants to
predict methotrexate response in JIA are those in 5-aminoimidazole-4-carboxamide
ribonucleotide-transformylase (ATIC), inosine-triphosphate-pyrophosphatase (ITPA)
and solute-liquid-carrier-19A1 (SLC19A1) genes. The purpose of the study was
therefore to explore the role of these candidate genetic factors on methotrexate
response in an Italian cohort of children with JIA.
Methods: Clinical response to methotrexate was evaluated as clinical remission stable
for a 6-months period, as ACRPed score and as change in JADAS score. The most
relevant SNPs for each gene considered were assayed on patients' DNA. ITPA activity
was measured in patients' erythrocytes.
Results: 69 patients with JIA were analyzed: 52.2% responded to therapy (ACRPed70
score), while 37.7% reached clinical remission stable for 6 months. ATIC rs2372536
GG genotype was associated with improved clinical remission (adjusted p-value =
0.0090). For ITPA, rs1127354 A variant was associated with reduced clinical
remission: (adjusted p-value = 0.028); this association was present even for patients
with wild-type ITPA and low ITPA activity.
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Conclusions: These preliminary results indicate that genotyping of ATIC rs2372536
and ITPA rs1127354 variants or measuring ITPA activity could be useful to predict
methotrexate response in children with JIA after validation by further prospective
studies on a larger patient cohort.
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Dear Prof. Loreto Carmona, 
thank you for your evaluation of our manuscript. We appreciate all the reviewers’ comments and we have 
edited the manuscript accordingly. Please find below the reviewers’ comment, followed by our reply and by 
the changes done to our revised manuscript. 
We hope that on the bases of these changes the manuscript will be now acceptable for publication and 
look forward to hear from you. 
Best regards. 
 
Reviewer #1: This is a small study in JIA that complements and supports previous observations.   
In methods: clinical data were collected at baseline, after 6 months of methotrexate therapy, and then 
every 3 months during treatment. Clarify the number of months/study visits the patients were evaluated ? 
Also, clinical remission was defined as 6 months without active disease. If a patient  was only followed for 6 
months, do we assume that clinical remission was achieved immediately after starting MTX. More details 
need to be provided regarding the number of study follow-ups in this small cohort. 
Reply: We appreciate the reviewer’s comments. Methotrexate treatment lasted a minimum of 6 months. 
Clinical data were collected at baseline, after 6 months of methotrexate therapy and then every 3 months 
during treatment. Minimum follow up for each patient was 12 months. Therefore, each patients had at 
least 4 visits. We added a sentence specifying this in the methods (page 6, lines 78-79). 
Reviewer #3: Dear Authors, I read with interest your manuscript on specific gene variants in predicting MTX 
response among children with JIA. 
Indeed the task of optimizing treatment in children with JIA is crucial in everyday clinical activity, and any 
tool that could help the physician to find the best treatment approach in the single patient and in the 
shortest period of time since onset will be very useful. 
Here are my major concerns on your manuscript: 
_ Although your results are interesting, since you found some association with the explored genetic 
variants and different indicators of clinical response, the associations are quite heterogeneous (in terms of 
specific gene variants and specific clinical indicators of response). I think this is secondary to the relatively 
small number of patients recruited, that your results have to be interpreted as preliminary results and need 
further confirmatory studies on larger cohort of patients. This point need more discussion on the 
manuscript than what already stated  
Reply: We agree with the reviewers’ comment. We added the sentence “We acknowledge that the 
associations described in this study about explored genetic variants and different indicators of clinical 
response are heterogeneous: this is likely secondary to the relatively small number of patients recruited. 
The results therefore have to be interpreted as preliminary and need further confirmatory studies on larger 
cohort of patients” in the discussion of the revised manuscript (page 17, lines 325 – 329). Moreover, we 
added “these preliminary results indicate that” to the conclusion in the abstract (page 2, line 24). 
_ I agree that the absence of a control population is a limitation of your study, please explain better why it 
is so  
Reply: The lack of a validation cohort limits at this point the extensibility of the observation described in the 
paper to the general population. We have added a sentence specifying this to the discussion of the paper 
(page 17, lines 330 – 331). 
Authors' Response to Reviewers' Comments
_ In the discussion you stated low ITPA measured in erythrocytes was associated with reduced 
methotrexate response. I understand this conclusion comes from the observation that patients with higher 
ITPA activity had higher rates of response, but in fact you fail to find a statistically significant association 
between ITPA activity and clinical response. Please discuss this discrepancy in the discussion. 
Reply: We acknowledge the reviewer’s comment. Indeed, mean ITPA activity was not different in this study 
between responders and non responders to methotrexate. However, in this paper patients with variant 
ITPA genotype had lower remission rate that patients with wild-type ITPA; moreover, we observed that all 
patients with wild type ITPA genotype and an enzymatic activity comparable to that observed in patients 
with variant ITPA, did not respond to therapy as these patients. We decided to present this observation in 
the paper, supporting the role of low ITPA activity, besides ITPA variant genotype, as a determinant of lack 
of response to methotrexate. We acknowledge that the role of ITPA activity in methotrexate response in 
JIA needs to be further evaluated in larger studies. On these basis we edited the relevant sentence in the 
discussion of the revised manuscript (page 15-16, lines 299-306). 
_ I personally do not agree on the possible outcome your results could have on deciding the treatment 
strategy in patients with JIA. In particular I do not agree that, if the results will be confirmed, we will be 
justified to skip the use of Methotrexate in children who will show a genotype predicting a low response to 
this drug, and starting biologics as first-line regimen. I agree that knowing the susceptibility to 
methotrexate in the single patients will be useful in switching more rapidly to a more aggressive treatment 
(i.e. MTX+biologics) in case of partial or no response, but,  according to clinical practice and regulations, I 
think Methotrexate will remain the first-line treatment in children requiring DMARDs. Moreover I do not 
think that the genotype of a single patient for the explored gene variants will be used to predict the 
response to treatment in that patient. 
Reply: We agree with the reviewer and we changed the discussion by underling that patients predisposed 
to lack of efficacy of methotrexate treatment could be switched more rapidly to a more aggressive therapy, 
maintaining methotrexate as a first line therapy (page 16, lines 322-324).  
Minor concerns: 
- Since the manuscript is directed towards pediatric rheumatologists I think the in-depth discussion 
of the core-set variables, the criteria for inactive disease and the JADAS are redundant 
Reply: In the revised manuscript we erased the in-depth description of the clinical scores in the methods as 
requested by the reviewer (page 6). 
- Even though well explained in the "material and methods", please specify in the results that 
ACRPed Score is evaluated at 6 months. 
Reply: We have made the change suggested by the reviewer (page 11, lines 198-199). 
- Page 1 line10 (abstract): "…methotrexate was evaluated [as]  clinical remission…" 
- Page 4 line 6: "...pharmacogenetics[,] published studies indicate…" 
- Page 14 line 7: "…in terms [of] clinical remission…" 
- Page 15 line 15:"…may be limited…" 
- Page 16 line 2 :"…comparable to that measure[d in] patients…" 
Reply: We have made all the edits suggested by the reviewer in the revised manuscript. 
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Abstract 5 
Objectives: For children with Juvenile Idiopathic Arthritis (JIA) who fail to respond to 6 
methotrexate, the delay in identifying the optimal treatment at an early stage of disease can 7 
lead to long-term joint damage. Recent studies indicate that relevant variants to predict 8 
methotrexate response in JIA are those in 5-aminoimidazole-4-carboxamide ribonucleotide-9 
transformylase (ATIC), inosine-triphosphate-pyrophosphatase (ITPA) and solute-liquid-10 
carrier-19A1 (SLC19A1) genes. The purpose of the study was therefore to explore the role of 11 
these candidate genetic factors on methotrexate response in an Italian cohort of children 12 
with JIA.   13 
Methods: Clinical response to methotrexate was evaluated as clinical remission stable for a 14 
6-months period, as ACRPed score and as change in JADAS score. The most relevant SNPs for 15 
each gene considered were assayed on patients’ DNA. ITPA activity was measured in 16 
patients’ erythrocytes. 17 
Results: 69 patients with JIA were analyzed: 52.2% responded to therapy (ACRPed70 score), 18 
while 37.7% reached clinical remission stable for 6 months. ATIC rs2372536 GG genotype 19 
was associated with improved clinical remission (adjusted p-value = 0.0090). For ITPA, 20 
rs1127354 A variant was associated with reduced clinical remission: (adjusted p-value = 21 
0.028); this association was present even for patients with wild-type ITPA and low ITPA 22 
activity.  23 
Conclusions: These preliminary results indicate that genotyping of ATIC rs2372536 and ITPA 24 
rs1127354 variants or measuring ITPA activity could be useful to predict methotrexate 25 
response in children with JIA after validation by further prospective studies on a larger 26 
patient cohort. 27 
 3 
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Introduction 32 
Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease of childhood 33 
and is an important cause of disability [1]. Methotrexate is the first choice disease-modifying 34 
anti-rheumatic drug in the JIA [2, 3], however, 35-45% of patients fail to respond, and the 35 
delay in identifying the optimal treatment in an early stage of disease can influence the long-36 
term joint damage [4, 5].  37 
Methotrexate is a folate analogue and enters the cell primarily via the reduced folate carrier 38 
(SLC19A1) [6]; pharmacological activity is increased by its enzymatic conversion to 39 
polyglutamated forms [7]. Methotrexate polyglutamates inhibit several key enzymes 40 
including thymidylate synthase (TYMS) that affects pyrimidine synthesis, dihydrofolate 41 
reductase (DHFR) that affects folate synthesis and 5-aminoimidazole-4-carboxamide 42 
ribonucleotide-transformylase (ATIC) that affects purine synthesis [6] . The latter is the 43 
pathway most potently inhibited by methotrexate polyglutamates, which results in a 44 
reduced conversion of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) to formyl-45 
AICAR by the enzyme ATIC [8]. Anti-inflammatory effects of methotrexate are thought to be 46 
related to accumulation of adenosine, a potent anti-inflammatory mediator, mainly 47 
consequent to ATIC inhibition [9].  48 
Recent studies have evaluated effects of genetic variants in the complex pathway of 49 
candidate genes involved in methotrexate pharmacokinetics and pharmacodynamics on the 50 
response to the medication in adults with rheumatoid arthritis and children with JIA [8, 10, 51 
11]. Hinks et al. presented an association of two SNPs in the ATIC gene and one SNP within 52 
the inosine-triphosphate-pyrophosphatase (ITPA) gene with reduced response to 53 
methotrexate in JIA; only one of the ATIC SNPs showed any trend towards MTX response in 54 
an independent cohort of North American JIA children (the ITPA SNP was not genotyped in 55 
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the validation cohort) [8]. Another study by De Rotte et al. identified an association between 56 
solute carrier 19A1 (SLC19A1) rs1051266 and response to methotrexate in 287 patients with 57 
JIA studied longitudinally [10]. 58 
Although fine mapping of genetic variants or genome-wide studies into MTX response in JIA 59 
or RA are lacking [12, 13] and despite inconsistencies in results from reports about MTX 60 
pharmacogenetics, published studies indicate that relevant variants to predict methotrexate 61 
response in JIA are those in ATIC, ITPA and SLC19A1 genes .  62 
The aim of the present study was therefore to evaluate the role of these candidate genetic 63 
factors on the response to methotrexate in terms of clinical remission in an Italian cohort of 64 
children with JIA. 65 
66 
 6 
Materials and Methods 67 
 68 
Patients and study design 69 
Children who fulfilled International League of Associations for Rheumatology (ILAR) criteria 70 
for JIA, and who received methotrexate or were going to start methotrexate for active 71 
arthritis, were enrolled at Burlo Garofolo Children’s Hospital. Children affected by systemic 72 
subtype of JIA were excluded. The study was carried out in compliance with the Helsinki 73 
Declaration and had full ethical approval by Burlo Garofolo Ethical Committee. Fully 74 
informed parental consent and child assent when appropriate was obtained. Demographic 75 
and clinical data were collected at baseline (up to 4 weeks before starting methotrexate)  76 
and after 6 months of methotrexate therapy, and then every 3 months during treatment. 77 
Methotrexate treatment lasted a minimum of 6 months. Minimum follow-up for each 78 
patient was 12 months. Weekly methotrexate was given by either oral or subcutaneous 79 
route at 10–15 mg/m2. Data allowing assessment of clinical response to the drug were 80 
collected using the validated core set variables[14] and the definition of clinical remission on 81 
medication for JIA, according to Wallace criteria[15]. To declare achievement of clinical 82 
remission, the patient must have not received other medications (NSAID, oral steroids, intra-83 
articular steroids) for a 6-month period of inactive disease on methotrexate [15]. The 84 
absolute disease activity at baseline and in follow-up is evaluated with Juvenile Arthritis 85 
Disease Score (JADAS) [16]. 86 
Venous blood samples were taken when the child required blood sampling for routine 87 
clinical care. 88 
 89 
SNP selection 90 
 7 
A total of 3 SNPs in 3 genes in the methotrexate pathway were selected for genotyping, on 91 
the basis of results from recent comprehensive studies [8, 9, 17]. In particular, analysis was 92 
performed for the coding non-synonymous SNPs rs2372536 in ATIC, rs1127354 in ITPA and 93 
rs1051266 in SLC19A1 [18]. 94 
 95 
Genotyping 96 
Genomic DNA was extracted from peripheral blood samples using a commercial kit (Sigma, 97 
Milan, Italy) and stored at -20 °C until use. Genotyping for rs2372536 in ATIC and rs1127354 98 
in ITPA was carried out using the TaqMan Pre-Developed Assay Reagents for genotyping 99 
(assay ID respectively: C_16218146_10 and C_27465000_10; Applied Biosystems, Foster 100 
City, CA), according to the manufacturer instructions. Genotyping of rs1051266 in SLC19A1 101 
was done using a PCR-RFLP assay [19]. 102 
 103 
Measurement of ITPA activity 104 
Red cell ITPA activity was measured by evaluation of the hydrolysis of ITP to IMP in lysates of 105 
patients’ erythrocytes with HPLC, according to the method by Shipkova et al. [20]. The 106 
reaction mixture contains ITP and, 15 minutes after the addition of a fixed amount of lysates, 107 
the sample is extracted by addition of perchloric acid, neutralized and loaded on the HPLC 108 
for quantification of IMP. ITPA activity is expressed as units (U): 1 U corresponds to 1 µmol 109 
IMP / g hemoglobin / hour. 110 
 111 
Statistical analysis 112 
Statistical analysis was performed using the software R (version 3.0).  113 
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Each SNP was tested for conformance of genotype frequencies to those expected under 114 
Hardy-Weinberg equilibrium with a Chi-square goodness-of-fit test. 115 
Analysis for association of clinical response, evaluated as a categorical variable (i.e, attaining 116 
an ACRPed score of at least 70 and clinical remission on methotrexate for a 6-month period), 117 
was performed by logistic regression. For these analyses, binomial models were generated 118 
using response to methotrexate as the dependent variable and the clinical, demographic or 119 
genetic covariate of interest (i.e., gender, age, disease duration at methotrexate start, 120 
methotrexate route of administration, methotrexate dose, frequency of homozygous variant 121 
genotype for ATIC, ITPA or SLC19A1, ITPA activity) as the independent variable. Odds ratios 122 
were calculated from estimates of the logistic regression models; for models with zero 123 
counts in a level of the variables, Haldane’s modification was used to calculate odds ratio, 124 
which add 0.5 to all cells to accommodate for the zero count[21]. 125 
For the analysis considering continuous variables (disease activity as JADAS score, evaluated 126 
at the start of methotrexate therapy or after 6 months of treatment and ITPA enzymatic 127 
activity), generalized linear models of the Gaussian family were used. Before applying linear 128 
models, normality of the continuous variable was assessed by visual examination of the 129 
histogram and Shapiro test; if distribution resulted non-normal, Box-Cox transformation was 130 
applied to increase normality. Analysis of the effect of genotypes on the difference in JADAS 131 
score between 6 months of therapy and at methotrexate start, adjusted for baseline JADAS 132 
score, was done by linear models, with JADAS score at 6 months as the dependent variable 133 
and the candidate genotype and JADAS score at methotrexate start as the independent 134 
variables.  135 
For all statistical test, adjustment for multiple testing was done by calculating adjusted p-136 
values with Holm’s method. 137 
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 138 
Results 139 
 140 
Patients enrolled 141 
Seventy three patients with JIA treated with methotrexate were considered. These are all 142 
consecutive patients treated with methotrexate at Burlo Garofolo Children’s Hospital  since 143 
2000. Four patients have been excluded from the study: one with systemic subtype of JIA, 144 
two treated with a biologic drug (etanercept) in association with methotrexate and one with 145 
incomplete data available. We present therefore retrospective results from 69 children 146 
whose full core set variable data and DNA sample were available. Demographic and clinical 147 
data are reported in Table 1. Most patients have been treated with subcutaneous 148 
administration (43/69, 62.3 %) of the medication; oral administration has been used in the 149 
rest of the cohort (26/69, 37.7%). 150 
 151 
Clinical response 152 
Clinical Remission 153 
Clinical remission was achieved by 37.7% of patients (26/69).  Patients’ gender, age at 154 
disease onset, age at methotrexate start, disease subtype, disease duration, methotrexate 155 
administration route and dose did not have a significant effect on response to therapy 156 
evaluated as clinical remission (Table 1). 157 
 158 
ACRPed Score 159 
The results for each response definition for patients considered are ACRPed30 for 79.7% 160 
(55/69) of patients, ACRPed50 for 73.9% (51/69) and ACRPed70 for 52.2% (36/69); 20.3% 161 
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(14/69) failed to reach even ACRPed30 score. Note that all children who reach ACRPed70 162 
automatically also reach ACRPed30 and ACRPed50, while those who achieve ACRPed50 also 163 
achieve ACRPed30. Patients’ gender, age at disease onset, age at methotrexate start, disease 164 
subtype, disease duration at methotrexate start, methotrexate administration route and 165 
dose did not have a significant effect on response to therapy evaluated as ACRPed score 166 
(Supplementary Table 1). 167 
 168 
JADAS score for disease activity 169 
Disease activity at the start of treatment with methotrexate, evaluated with the JADAS 170 
score, indicated a median value of 18.3 (range 3.0 – 49.8); after 6 months of treatment with 171 
methotrexate a pronounced reduction in the disease activity was achieved (p-value = 3.0x10-172 
16,  linear model), with a median value of 5.3 (range 0 – 36.8). 173 
 174 
Genotyping 175 
SNPs genotyped in this cohort, rs2372536 in ATIC, rs1127354 in ITPA and rs1051266 in 176 
SLC19A1 were characterized in all patients (69/69). All polymorphisms considered follow 177 
Hardy-Weinberg equilibrium and their frequency is in agreement with the distribution of 178 
these SNPs in the Caucasian population, with minor allele frequency of 37.7%, 4.3% and 179 
49.3% respectively for ATIC rs2372536 (C>G), ITPA rs1127354 (C>A) and SLC19A1 rs1051266 180 
(A>G). 181 
 182 
Clinical response and genotyping 183 
Clinical remission 184 
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Considering clinical remission, results for significant associations are shown in Table 2. ATIC 185 
rs2372536 presented a significant effect (p-value adjusted for multiple testing 0.0090, 186 
logistic regression): homozygous variant G genotype was more frequent in patients achieving 187 
clinical remission (31% in patients with clinical remission vs 5% in patients with no clinical 188 
remission, odds ratio 9.11, 95% C.I. 1.76 – 47.23). ITPA rs1127354 also presented a 189 
significant effect (p-value adjusted for multiple testing = 0.028, logistic regression): no 190 
patient in clinical remission presented a variant CA or AA genotype, while these variants 191 
were present in 14.1% of patients that did not reach clinical remission. Multivariate logistic 192 
regression confirmed independent effects for SNPs ATIC rs2372536 and ITPA rs1127354 in 193 
terms of their association with response to methotrexate evaluated as induction of clinical 194 
remission (adjusted p-value respectively 0.0030 and 0.031, logistic regression). 195 
 196 
ACRPed scores 197 
Trends for an association with improved response evaluated as ACRPed70score, evaluated at 198 
6 months, was identified for SLC19A1 rs1051266 and ATIC rs2372536, however these 199 
tendencies were not significant after adjusting for multiple testing (Table 3). No significant 200 
effect was identified for the variant in ITPA on response to methotrexate in terms of 201 
ACRPed70 score (Table 3). 202 
 203 
JADAS scores 204 
Considering disease activity evaluated by JADAS score at the start of treatment with 205 
methotrexate and after 6 months of therapy, SLC19A1 rs1051266 SNP demonstrated 206 
statistically significant effects (Figure 1). Patients with a variant GG genotype for SLC19A1 207 
rs1051266 presented higher JADAS scores after 6 months of therapy in comparison to 208 
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patients with either AA or AG genotypes (p-value adjusted for multiple testing = 0.012, linear 209 
model). SLC19A1 rs1051266 had no significant effect on JADAS score at the beginning of 210 
methotrexate therapy. Analysis of the JADAS score after 6 months of therapy, adjusted for 211 
baseline JADAS score, showed that both baseline JADAS score and SLC19A1 genotype had a 212 
significant association with JADAS score after 6 months of therapy (Figure 1, p-value 213 
adjusted for multiple testing respectively < 0.0001 e 0.036, linear models).  214 
No significant effect of the ATIC and ITPA SNPs considered on JADAS score was identified 215 
(Supplementary Figures 1 and 2). 216 
ITPA activity 217 
ITPA activity was measured successfully in erythrocytes from 62/73 patients. As expected, a 218 
highly significant association of the enzymatic activity with SNP rs1127354 in ITPA was 219 
detected, so that the variant A allele additively induced a reduction in the enzyme activity: 220 
indeed ITPA activity was 162.7, 52.4 and 0.75 U among patients with CC, CA and AA 221 
genotype respectively (Figure 2, p-value = 1.0 x 10-5, linear model). ITPA activity was not 222 
associated with patients’ gender, age, disease subtype. Moreover, no association of ITPA 223 
activity was detected with methotrexate dose or clinical response to methotrexate, 224 
measured either with ACRPed score or as clinical remission. However, all 9 patients with low 225 
ITPA activity (<92 U, highest value observed in patients with variant ITPA genotype) did not 226 
achieve clinical remission, while frequency of remission was 43.4% (23/53) among patients 227 
with ITPA activity higher than 92 U (Table 4, p-value = 0.0024, logistic regression). 228 
229 
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Discussion 230 
Polymorphisms in genes encoding for enzymes involved in methotrexate pharmacokinetics 231 
and pharmacodynamics have been associated with drug response. Recent studies have 232 
evaluated the effect of various candidate variants in adults with rheumatoid arthritis and 233 
children with JIA [8, 10, 17, 18]. Hinks et al. have characterized genetic variability in 13 234 
candidate genes involved in methotrexate pharmacokinetic and pharmacodynamic 235 
pathways, using for each gene the tagSNPs, selected on the basis of the haplotype map [8]. 236 
This study considered two large cohorts of patients with JIA, one from UK and one from US. 237 
Results obtained have shown that two SNPs in the ATIC gene and one SNP within ITPA were 238 
significantly associated with methotrexate response in the discovery cohort from UK. One of 239 
the SNPs in ATIC, an intronic variant (rs12995526), showed a trend with association even in 240 
the validation cohort from US. Another study by De Rotte et al. identified an association 241 
between SLC19A1 rs1051266 and response to methotrexate in 287 patients with JIA studied 242 
longitudinally [10]. Moreover, two recent studies in adult patients with rheumatoid arthritis 243 
have used a similar approach [17, 18]. On these bases, we studied the effects of the main 244 
functional variant of ATIC, ITPA and SLC19A1 (respectively rs2372536, rs1127354 and 245 
rs1051266) on response to methotrexate in a cohort of Italian patients with JIA. ATIC and 246 
ITPA are two genes encoding enzymes involved in purines biosynthesis and metabolism, 247 
while SLC19A1 (known also as reduced folate carrier 1) is a transporter responsible for 248 
methotrexate influx in cells [6]. Our study considered a cohort of 69 patients, which 249 
constitutes all consecutive patients with JIA that have been treated with methotrexate at 250 
Burlo Garofolo Children’s Hospital from 2000 to 2013.  251 
Results show that frequency of response to methotrexate evaluated in this study is similar to 252 
that reported in the literature [1, 22]. As expected, the majority of patients enrolled are 253 
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females; however, demographic, clinical and pharmacological covariates had no significant 254 
effects on response to therapy. In particular, route of methotrexate administration had no 255 
significant effect on response to the medication; this observation is in agreement with 256 
recent reports [10, 23]. 257 
As far as the effect of the candidate genotypes considered is concerned, our study showed a 258 
significant effect of the functional variant in ATIC (rs2372536): variant GG genotype was 259 
associated with better response in terms of clinical remission (odds ratio 9.1), with trends for 260 
an effect on ACRPed70 (Table 2) and ACRPed30 scores (Supplementary Table 2). Even the 261 
functional variant in ITPA (rs1127354) presented an effect on response to methotrexate: 262 
variant A allele had a lower percentage of clinical remission in comparison to wild type C 263 
allele. Multivariate analysis supported the view that the significant effects of ATIC and ITPA 264 
variants on clinical remission were independent. Genetic polymorphisms of ATIC and ITPA 265 
may impact MTX response independently since these enzymes are involved in different, 266 
though interconnected, enzymatic pathways in cells (i.e., respectively de novo synthesis and 267 
salvage pathways for purines) [18]. 268 
Previous reports in the literature investigated the pharmacogenetics of methotrexate in JIA 269 
[8, 10, 11, 24]. Our study is in agreement with previous studies that consider efficacy of 270 
methotrexate in patients with rheumatoid arthritis, indicating therefore that the ATIC  271 
rs2372536 GG genotype may be associated with improved response even in children with JIA 272 
[9, 17, 25]. This variant likely influences methotrexate efficacy since it predisposes the ATIC 273 
enzyme to the inhibition induced by the methotrexate active metabolites [26], which results 274 
in a more pronounced reduction of de novo purine synthesis and increased adenosine 275 
release, the main molecular mechanisms underlying methotrexate efficacy in JIA [9]. 276 
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A recent study by De Rotte et al. identified an association between SLC19A1 rs1051266 and 277 
response to methotrexate in 287 patients with JIA studied longitudinally [10]. In our study 278 
the SLC19A1 variant rs1051266 was not associated with response to methotrexate evaluated 279 
as clinical remission. However, a trend was present for ACRPed70 score (not significant after 280 
adjustment for multiple testing as in the study by De Rotte et al.); this observation is in 281 
agreement with many other studies reported in the literature, describing a controversial 282 
association of this variant with response to methotrexate in JIA and rheumatoid arthritis [8, 283 
19, 27-31]. Interestingly, in our patients’ population there seem to be an association of this 284 
SNP with the change in JADAS score between methotrexate start and after 6 months of 285 
therapy: patients homozygous for the variant GG genotype displayed a reduced 286 
improvement in JADAS score, in comparison with patients with either AA or AG genotype. 287 
However, this effect was not associated with modifications of the clinical remission rate. This 288 
is the first report about an effect of SCL19A1 rs1051266 genotype on JADAS score change 289 
and should be validated by other studies; moreover, clinical relevance of this observation 290 
may be limited, since this effect did not modify clinical remission induced by methotrexate 291 
[15]. 292 
Distribution of ITPA activity measured in erythrocytes of JIA patients enrolled in this study 293 
and its association with ITPA rs1127354 variant are consistent with previous reports in 294 
healthy subjects [20, 32]. To note, especially for the rs1127354 CC genotype, there is a large 295 
amount of variation in levels of enzymatic activity between individuals. This observation is 296 
consistent with previous reports in the literature [20] and may be related to the effect of 297 
genetic polymorphisms in genes different from ITPA on its enzymatic activity (“trans effect”), 298 
as it has been shown recently for TPMT [33]. Although average ITPA activity was not 299 
different between responders and non responders, low activity of ITPA measured in 300 
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erythrocytes was associated with reduced methotrexate response in this study, confirming 301 
the role of ITPA rs1127354 variant; indeed even patients with normal ITPA genotype and low 302 
ITPA activity, comparable to that measured in patients with variant ITPA, did not respond to 303 
therapy. This observation and the role of ITPA activity on methotrexate response need to be 304 
further evaluated by larger prospective studies, possibly considering even ITPA gene 305 
expression [13, 34]. 306 
This is the first report considering the pharmacogenetics of response to methotrexate in JIA 307 
in terms of clinical remission. This clinical phenotype may be more relevant to describe the 308 
benefit induced by the treatment and to guide patient care, in comparison to the ACRPed 309 
score or changes in JADAS score, since it represents a longer period in which the patient 310 
does not present signs of disease activity, including uveitis, the most significant complication 311 
of JIA [15].  312 
Identification of patients who are likely to respond to methotrexate before treatment in JIA 313 
would be very useful for the clinician and our study supports the development of multilocus 314 
pharmacogenetic signatures to predict response to methotrexate in these patients. 315 
Genotyping should be performed at diagnosis and patients with a genotype predisposing to 316 
response, such as the ATIC rs2372536 GG genotype, should be treated with methotrexate, 317 
given the high probability of response to this treatment. This study provides a rational for 318 
reserving biologics to patients that will likely not benefit from less expensive but still 319 
effective treatments such as methotrexate. On the contrary, patients with variants 320 
associated with lack of efficacy of methotrexate (such as ITPA rs1127354 A allele and in 321 
general those with low ITPA activity), should be switched more rapidly to a more aggressive 322 
treatment (i.e., methotrexate + biologics or biologics alone). Methotrexate remains however 323 
the first line treatment in children with JIA requiring DMARDs..  324 
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We acknowledge that the associations described in this study about explored genetic 325 
variants and different indicators of clinical response are heterogeneous: this is likely 326 
secondary to the relatively small number of patients recruited. The results therefore have to 327 
be interpreted as preliminary and need further confirmatory studies on larger cohort of 328 
patients.   329 
A key limitation of this study is the lack of a validation cohort supporting its findings, limiting 330 
at this point the extensibility of this observation to the general population. Moreover, given 331 
the paucity of studies that comprehensively fine mapped candidate genes to identify the 332 
causal variants in each or genome-wide association studies into MTX response in JIA or RA, it 333 
is possible that additional genetic effects will be contained within other genomic regions not 334 
yet investigated [12]. If the results described in the present study will be validated by larger 335 
prospective trials, application of pharmacogenetic guided treatment of JIA may allow 336 
rationalization and reduction of costs associated with care, by directing and personalizing 337 
the use of methotrexate and biologics. 338 
339 
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 464 
Table 1: Demographics of patients with juvenile idiopathic arthritis (JIA) 
 Overall Remission No Remission 
Number of cases 69 26 43 
JIA subtype at the beginning of therapy 
with methotrexate 
   
Oligoarticular persistent 37 (54%) 15 (58%) 22 (51%) 
Oligoarticular extended 7 (10%) 2 (2%) 5 (12%) 
Polyarticular RF - * 23 (33%) 9 (35%) 14 (32%) 
Enthesitis related arthritis 1 (1%) 0 1 (2%) 
Psoriatic 1 (1%) 0 1 (2%) 
Female  53 (77%) 21 (81%) 53 (77%) 
Age at disease onset, median and range 
(years) 
3, 1 – 16 3.5, 1 - 13 3, 1 – 16 
Age at the start of methotrexate, 
median and range (years) 
8, 1 – 22 9, 2 - 22 8, 1 – 19 
Disease duration at the start of 
methotrexate, median and range 
(years) 
1, 0 – 19 1, 0 - 19 1, 0 – 12 
Physician’s global assessment of disease 
activity, VAS score 
6, 2 – 10 6.5, 2 - 9 6, 2 – 10 
Patient/parent ’s global assessment of 
disease activity, VAS score 
7, 0 – 10 7, 0 - 10 6, 2- 10 
CHAQ 0.6, 0 – 3 0.55,0-2.9 0.7, 0 – 3 
 23 
Median and range of active joints at 
start of methotrexate 
3, 0 – 26 ** 2.5, 0 -16** 3, 1 – 26 
Median and range of restricted joints at 
start of methotrexate 
2, 0 – 28 2, 0 - 22 2, 0 -28 
ESR (mm/h) 41, 2-120 40.5,2-106 45, 2-120 
Administration route (subcutaneous vs 
oral) 
43 (62%) 17 (65%) 26 (60%) 
Median and range of methotrexate 
dose (mg/m2) 
15, 10 – 20 15,10-20 15,10-20 
Concomitant treatment    
Intra-articular glucocorticoid 44 (64%) 20 (77%) 24 (56%) 
NSAIDs 66 (96%) 23 (88%) 43 (100%) 
Oral glucocorticoid 41 (59%) 14 (54%) 27 (63%) 
CHAQ: Childhood Health Assessment Questionnaire; ESR: erythrocyte sedimentation rate; 465 
NSAIDs: non-steroidal anti-inflammatory drug; VAS: visual analogue scale.  466 
*: no patient with polyarticular RF+ subset of disease was found. 467 
**: one patient with 0 active joints but affected by dry synovitis (subset of RF- polyarticular 468 
JIA) with important stiffness and 8 joints with limitation of motion. 469 
470 
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Table 2: Clinical response evaluated as remission and the considered genotypes in 69 patients with JIA. 
Analysis were performed according to a recessive inheritance model. 
SNP Gene WT+het/var Genotype 
Frequency 
Remission 
n = 26 
Genotype 
Frequency    
No Remission 
n = 43 
p-value p-value 
adjusted 
Odds 
ratio 
(95% CI) 
rs2372536 ATIC CC+CG/GG 0.69/0.31 0.95/0.05 0.0030 0.0090 9.11 
(1.76-47.2) 
rs1127354 ITPA CC/CA+AA* 1/0 0.86/0.14 0.014 0.028 0.17  
(0.012-2.53) 
rs1051266 SLC19A1 AA+AG/GG 0.81/0.19 0.74/0.26 0.54 0.54 0.69 
(0.21-2.28) 
*: for ITPA rs1127354, analysis was done by grouping heterozygous CA patients with 472 
homozygous variant AA, given the low frequency of homozygous patients (1 in 69 patients) 473 
and the strong functional effect of the variant allele even in its heterozygous form (see 474 
Figure 2). P-values are from logistic regression and adjustment for multiple testing was done 475 
using Holm’s method. CI: confidence interval; WT: wild-type; het: heterozygous; var = 476 
variant. 477 
 478 
479 
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Table 3: Clinical response evaluated as ACRPed70 score and the considered genotypes in 69 patients with 
JIA. Analysis were performed according to a recessive inheritance model. 
SNP Gene WT+het/var Genotype 
Frequency 
ACRPed70 
n = 37 
Genotype 
Frequency    
No ACRPed70 
n = 32 
p-value p-value 
adjusted 
Odds 
ratio 
(95% CI) 
rs2372536 ATIC CC+CG/GG 0.78/0.22 0.94/0.06 0.061 0.12 4.14 
(0.81-21.15) 
rs1127354 ITPA CC/CA+AA* 0.95/0.05 0.88/0.12 0.30 0.30 0.40 
(0.068-2.35) 
rs1051266 SLC19A1 AA+AG/GG 0.86/0.14 0.66/0.34 0.039 0.12 0.30 
(0.091-0.98) 
*: for ITPA rs1127354, analysis was done by grouping heterozygous CA patients with 481 
homozygous variant AA, given the low frequency of homozygous patients (1 in 69 patients) 482 
and the strong functional effect of the variant allele even in its heterozygous form (see 483 
Figure 2). P-values are from logistic regression; adjustment for multiple testing was done 484 
using Holm’s method. CI: confidence interval; WT: wild-type; het: heterozygous; var = 485 
variant. 486 
487 
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Table 4: Clinical response to methotrexate evaluated as remission stable for 6 months and 
ITPA activity 
 Clinical response 
ITPA activity Patients reaching 
remission 
Non responder Odds ratio 
(95% C.I.) 
 
p-value 
High (> 92 U) 23 30 14.64 
(0.81–264.53) 
0.0024 
Low (< 92 U) 0 9 
One unit (U) of ITPA activity corresponds to 1 µmol IMP / g hemoglobin / hour. The cut-off 489 
between patients with low and high ITPA activity was defined based on the highest value of 490 
activity observed among patients with variant ITPA (i.e., 92 U, Figure 2). 491 
 492 
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Figure 1: JADAS score before methotrexate treatment (panel A), after 6 months of therapy 495 
with methotrexate (panel B), JADAS score after treatment adjusted for baseline JADAS value 496 
(panel C) and SLC19A1 rs1051266 genotype. P-values are from linear models. Adjustment for 497 
multiple comparison was done using Holm’s method. 498 
499 
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Figure 2: Association between ITPA enzymatic activity in erythrocytes and ITPA rs1127354 501 
SNP. 502 
 503 
 504 
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Supplementary Table 1: Demographics of patients with juvenile idiopathic arthritis (JIA) and response to 
methotrexate treatment (ACRPed70 vs no ACRPed70) 
 Overall ACR70 No ACR70 
Number of cases 69 37 32 
JIA subtype at the beginning of therapy with 
methotrexate 
   
Oligoarticular persistent 37 (54%) 23 (62%) 14 (44%) 
Oligoarticular extended 7 (10%) 1 (3%) 6 (19%) 
Polyarticular RF - * 23 (33%) 13 (35%) 10 (31%) 
Enthesitis related arthritis 1 (1%) 0 1 (3%) 
Psoriatic 1 (1%) 0 1 (3%) 
Female  53 (77%) 28 (76%) 25 (78%) 
Age at disease onset, median and range (years) 3, 1 – 16 3, 1 - 16 4.5, 1 - 13 
Age at the start of methotrexate, median and 
range (years) 
8, 1 – 22 8, 1 - 22 8.5, 2– 19 
Disease duration at the start of methotrexate, 
median and range (years) 
1, 0 – 19 1, 0 - 19  1, 0 – 12 
Physician’s global assessment of disease 
activity, VAS score 
6, 2 – 10 6, 2 - 10 7, 2 – 10 
Patient/parent ’s global assessment of disease 
activity, VAS score 
7, 0 – 10 7, 0 - 10 6, 0 -10 
CHAQ 0.6, 0 – 3 0.7, 0 - 3 0.6, 0 -3 
Median and range of active joints at start of 
methotrexate 
3, 0 – 26 ** 2, 0 - 26 3, 1 – 10 
Median and range of restricted joints at start 
of methotrexate 
2, 0 – 28 2, 0 - 28 2, 0 – 16 
ESR (mm/h) 41, 2-120 39, 2-120 45, 9-114 
Administration route (subcutaneous vs oral) 43 (62%) 24 (65%) 19 (59%) 
Median and range of methotrexate dose 
(mg/m2) 
15, 10 – 20 15, 10–20 15, 10–20 
Concomitant treatment    
Intra-articular glucocorticoid 44 (64%) 28 (76%) 16 (50%) 
FANS 66 (96%) 34 (92%) 32 (100%) 
Oral glucocorticoid 41 (59%) 22 (59%) 19 (59%) 
 
  
Supplementary Table 2: Clinical response evaluated as ACR30Ped score and the considered genotypes in 69 
patients with JIA. Analysis were performed according to a recessive inheritance model. 
SNP Gene WT+het/var Genotype 
Frequency 
ACRPed30 
n = 55 
Genotype 
Frequency Non 
Responders 
n = 14 
p-value p-value 
adjusted 
Odds 
ratio 
(95% CI) 
rs2372536 ATIC CC+CG/GG 1/0 0.82/0.18 0.026 0.080 5.32  
(0.34-82.75) 
rs1127354 ITPA CC/CA+AA* 0.93/0.07 0.86/0.14 0.43 0.86 0.47 
(0.077-2.88) 
rs1051266 SLC19A1 AA+AG/GG 0.76/0.24 0.79/0.21 0.86 0.86 1.14  
(0.27-4.70) 
*: for ITPA rs1127354, analysis was done by grouping heterozygous CA patients with homozygous variant 
AA, given the low frequency of homozygous patients (1 in 69 patients) and the strong functional effect of 
the variant allele even in its heterozygous form (see Figure 2). P-values are from logistic regression; 
adjustment for multiple testing was done using Holm’s method. CI: confidence interval; WT: wild-type; het: 
heterozygous; var = variant.  
 Supplementary Figure 1: JADAS score before (panel A), after 6 months of therapy with methotrexate (panel 
B) and JADAS score after treatment adjusted for baseline JADAS value (panel C) and ATIC rs2372536 
genotype. P-values are from linear models. Adjustment for multiple comparison was done using Holm’s 
method. 
  
  
Supplementary Figure 2: JADAS score before (panel A), after 6 months of therapy with methotrexate (panel 
B) and JADAS score after treatment adjusted for baseline JADAS value (panel C) and ITPA rs1127354 
genotype. P-values are from linear models. Adjustment for multiple comparison was done using Holm’s 
method. 
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